Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.57 USD
Change Today -0.3099 / -1.73%
Volume 23.9K
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 9:33 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Gregory I. Frost Ph.D.

Chairman of Scientific Advisory Board, Halozyme Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 15 board members in 1 different organizations across 2 different industries.

See Board Relationships
42$14,508,779
As of Fiscal Year 2014

Background*

Dr. Gregory I. Frost, also known as Greg, Ph.D. has been Senior Vice President of Health Sector at Intrexon Corporation since January 6, 2014. Dr. Frost co-founded Halozyme Therapeutics, Inc. in 1999 served as its Chief Executive Officer and President from December 3, 2010 to January 6, 2014. He served as the Chief Scientific Officer of Halozyme Therapeutics, Inc. from December 2002 to December 3, 2010 its Vice President until December 3, 2010. He joined Halozyme in ...

Read Full Background

Corporate Headquarters*

11388 Sorrento Valley Road
San Diego, California 92121

United States

Phone: 858-794-8889
Fax: 858-704-8311

Board Members Memberships*

1999-2014
Chairman of Scientific Advisory Board

Education*

PhD
University of California-San Francisco
BA
University of California, Santa Cruz

Other Affiliations*

Annual Compensation*

Salary$494,231
Bonus$491,781
Total Annual Compensation$986,012

Stock Options*

All Other Compensation$19,967
Unexercisable Options1,000,000
Unexercisable Options Value$4,760,000
Total Value of Options$4,760,000
Total Number of Options1,000,000

Total Compensation*

Total Annual Cash Compensation$1,005,979
Total Short Term Compensation$986,012
Other Long Term Compensation$19,967
Total Calculated Compensation$14,508,779
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $17.57 USD -0.3099

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John W. Varian Chief Executive Officer and Director
XOMA Corporation
$569.5K
Simon E. Moroney Ph.D.Chairman of Management Board and Chief Executive Officer
Morphosys AG
€751.2K
Charles G. Marianik Chairman of the Board, Chief Executive Officer and President
Horiba Scientific
$219.0K
David L. Hallal Chief Executive Officer and Director
Alexion Pharmaceuticals, Inc.
$696.1K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.